Clinical TrialsA Phase 1b study of ABI-4334 in HBV patients is on target to initiate by mid-year 2024, with interim data expected by year-end 2024.
Drug DevelopmentABI-5366 has shown nanomolar potency against both HSV type 1 (HSV-1) and HSV type 2 (HSV-2) in-vitro, and importantly showed sustained plasma concentrations for over 30 days given either orally or subcutaneously in preclinical studies, thus supporting its potential as a long-acting therapeutic.
Financial PerformanceTwo equity financings adding $12.6M of gross proceeds.